Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14574585 | 0.87 | HTR2B (0.39) | FAAHSMN1; SMN2THRBMAPT | |
| SCHEMBL7718857 | 0.85 | GPR119 (0.52) | FAAHSMN1; SMN2GAATHRBGPR119 | |
| SCHEMBL14574597 | 0.80 | FAAH (0.79) | FAAH | |
| SCHEMBL4175718 | 0.77 | NAMPT (0.56) | THRBGPR119MAPTPTPN2PTPN1 | |
| SCHEMBL558040 | 0.75 | SMN1; SMN2 (0.55) | FAAHSMN1; SMN2GAATHRBGPR119 | |
| SCHEMBL3104584 | 0.75 | HTT (0.56) | FAAHSMN1; SMN2GAATHRBGPR119 | |
| SCHEMBL3102619 | 0.72 | SMN1; SMN2 (0.50) | FAAHSMN1; SMN2GAATHRBGPR119 | |
| SCHEMBL16597919 | 0.72 | BTK (0.49) | FAAHSMN1; SMN2GAATHRBGPR119 | |
| SCHEMBL14574543 | 0.72 | HTR2B (0.40) | FAAHSMN1; SMN2THRB | |
| SCHEMBL7711368 | 0.72 | RECQL (0.47) | FAAHSMN1; SMN2GAATHRBGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9193697-B2 | Oxazole derivatives useful as modulators of FAAH | MERCK SHARP & DOHME CORP. (US) | 2015-11-24 | — | — | US | disclosed |
| US-9193697-B2 | Oxazole derivatives useful as modulators of FAAH | MERCK SHARP & DOHME CORP. (US) | 2015-11-24 | — | — | US | disclosed |
| US-9193697-B2 | Oxazole derivatives useful as modulators of FAAH | MERCK SHARP & DOHME CORP. (US) | 2015-11-24 | — | — | US | disclosed |
| EP-2555772-A1 | OXAZOLE DERIVATIVES USEFUL AS MODULATORS OF FAAH | Merck Sharp & Dohme Corp. (US) | 2013-02-13 | — | — | EP | disclosed |
| US-20130018048-A1 | OXAZOLE DERIVATIVES USEFUL AS MODULATORS OF FAAH | MERCK SHARP & DOHME CORP. (US) | 2013-01-17 | — | — | US | disclosed |
| US-20130018048-A1 | OXAZOLE DERIVATIVES USEFUL AS MODULATORS OF FAAH | MERCK SHARP & DOHME CORP. (US) | 2013-01-17 | — | — | US | disclosed |
| US-20130018048-A1 | OXAZOLE DERIVATIVES USEFUL AS MODULATORS OF FAAH | MERCK SHARP & DOHME CORP. (US) | 2013-01-17 | — | — | US | disclosed |
| WO-2011126960-A1 | OXAZOLE DERIVATIVES USEFUL AS MODULATORS OF FAAH | MERCK SHARP & DOHME CORP. (US) | 2011-10-13 | — | — | WO | disclosed |
| WO-2011126960-A1 | OXAZOLE DERIVATIVES USEFUL AS MODULATORS OF FAAH | MERCK SHARP & DOHME CORP. (US) | 2011-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018048-A1 | OXAZOLE DERIVATIVES USEFUL AS MODULATORS OF FAAH | FAAH, FAAH2, ALOX5 | FAAH 1/4885SMN1; SMN2 304/4885GAA 1029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.